TSC22D3 and urinary bladder cancer: As a result of inducing transactivation or transrepression of GR by dexamethasone, up-regulation of FKPB51 and GILZ or down-regulation of NF-κB and AP-1 as well as MMP-2, MMP-9, IL-6, and VEGF, respectively, has been documented in bladder cancer cells [41,43,44].